Predicting virological decay in patients starting combination antiretroviral therapy

UK Collaborative HIV Cohort UK, Rachael A. Hughes*, Jonathan A. C. Sterne, John Walsh, Frank Post, Mark Nelson, Sophie Jose, Teresa Hill, Kate Tilling, Martin Fisherg, David Dunn, Roy Trevelion, Adrian Palfreeman, Fabiola Martin, Mark Gompels, Clifford Leen, Margaret Johnson, Richard Gilson, Jane Anderson, Jonathan AinsworthPhillip Hay, Chloe Orkin, Stephen Kegg, Caroline A. Sabin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Model trajectories of viral load measurements from time of starting combination antiretroviral therapy (cART), and use the model to predict whether patients will achieve suppressed viral load (

Design: Prospective cohort study including HIV-positive adults (UK Collaborative HIV Cohort Study).

Methods: Eligible patients were antiretroviral naive and started cART after 1997. Random effects models were used to estimate viral load trends. Patients were randomly selected to form a validation dataset with those remaining used to fit the model. We evaluated predictions of suppression using indices of diagnostic test performance.

Results: Of 9562 eligible patients 6435 were used to fit the model and 3127 for validation. Mean log(10) viral load trajectories declined rapidly during the first 2 weeks post-cART, moderately between 2 weeks and 3 months, and more slowly thereafter. Higher pretreatment viral load predicted steeper declines, whereas older age, white ethnicity, and boosted protease inhibitor/non-nucleoside reverse transcriptase inhibitors based cART-regimen predicted a steeper decline from 3 months onwards. Specificity of predictions and the diagnostic odds ratio substantially improved when predictions were based on viral load measurements up to the 4-month visit compared with the 2 or 3-month visits. Diagnostic performance improved when suppression was defined by two consecutive suppressed viral loads compared with one.

Conclusions: Viral load measurements can be used to predict if a patient will be suppressed by 6-month post-cART. Graphical presentations of this information could help clinicians decide the optimum time to switch treatment regimen during the first months of cART. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.

Original languageEnglish
Pages (from-to)1817-1827
Number of pages11
JournalAIDS
Volume30
Issue number11
DOIs
Publication statusPublished - 17 Jul 2016

Keywords

  • CD4(+) cell count
  • combination antiretroviral therapy
  • HIV-1
  • predicted virological suppression
  • treatment switch
  • viral load
  • HIV-1 RNA DYNAMICS
  • BASE-LINE FACTORS
  • VIRAL DYNAMICS
  • PROSTATE-CANCER
  • EQUAL ACCESS
  • IN-VIVO
  • RESPONSES
  • INFECTION
  • COHORT
  • LOAD

Cite this